SCHEMBL23382995

SCHEMBL23382995

CC1(OC(=O)c2ccc(C(=O)OCC(F)(F)C(=O)O)cc2)CCCCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 1/20 0.39
▸ MAPK1 P28482 2/20 0.39
▸ HIF1A Q16665 1/20 0.39
▸ NPSR1 Q6W5P4 4/20 0.36
▸ SMN1; SMN2 Q16637 4/20 0.36
▸ CYP2D6 P10635 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ ADORA3 P0DMS8 1/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ TDP1 Q9NUW8 2/20 0.34
▸ HTR1A P08908 1/20 0.34
▸ SCN1A P35498 1/20 0.34
▸ SLC6A3 Q01959 1/20 0.34
▸ SCN5A Q14524 1/20 0.34
▸ SCN2A Q99250 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23382487 0.99 MAPK1 (0.40) CYP19A1MAPK1HIF1ANPSR1SMN1; SMN2
SCHEMBL23382807 0.88 ADORA3 (0.36) CYP19A1MAPK1HIF1ANPSR1SMN1; SMN2
SCHEMBL23382702 0.87 ADORA3 (0.38) MAPK1HIF1ANPSR1SMN1; SMN2CYP2D6
SCHEMBL23382804 0.87 RARA (0.35) CYP19A1MAPK1HIF1ANPSR1SMN1; SMN2
SCHEMBL23383018 0.86 SCN1A (0.42) CYP19A1MAPK1HIF1ANPSR1MEN1
SCHEMBL23382992 0.86 SMN1; SMN2 (0.39) MAPK1HIF1ANPSR1SMN1; SMN2CYP2D6
SCHEMBL23382696 0.86 MAPK1 (0.38) MAPK1HIF1ANPSR1SMN1; SMN2CYP2D6
SCHEMBL23382996 0.85 MAPK1 (0.35) MAPK1HIF1ANPSR1SMN1; SMN2CYP2D6
SCHEMBL23383017 0.85 SCN1A (0.43) CYP19A1MAPK1HIF1ANPSR1MEN1
SCHEMBL23382999 0.85 NPSR1 (0.40) MAPK1HIF1ANPSR1SMN1; SMN2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11762287-B2 Onium salt compound, chemically amplified resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-09-19 — — US disclosed
US-11762287-B2 Onium salt compound, chemically amplified resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-09-19 — — US disclosed
US-20210149301-A1 ONIUM SALT COMPOUND, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2021-05-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11762287-B2 Onium salt compound, chemically amplified resist composition and patterning process IDUA, SLC6A5, SLC6A9 CYP19A1 4062/4885MAPK1 229/4885HIF1A 4225/4885
US-20210149301-A1 ONIUM SALT COMPOUND, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS IDUA, SLC6A5, SLC6A9 CYP19A1 4062/4885MAPK1 229/4885HIF1A 4225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback